CYPH CYPHERPUNK TECHNOLOGIES INC. NASDAQ · United States

CYPHERPUNK TECHNOLOGIES INC. (CYPH) news

CYPHERPUNK TECHNOLOGIES INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CYPH, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CYPHERPUNK TECHNOLOGIES INC. news

We have not published a story on CYPHERPUNK TECHNOLOGIES INC. yet. When there is news, it will appear here.

CYPHERPUNK TECHNOLOGIES INC. annual financials

Line	FY2025	FY2024
Research and development	$25.7 million	$57.2 million
Net income (loss)	$4.8 million	-$67.6 million
Cash from operations	-$43.9 million	-$60.3 million
Cash and equivalents	$14.0 million	$47.2 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $7.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about CYPHERPUNK TECHNOLOGIES INC.

What is the ticker symbol of CYPHERPUNK TECHNOLOGIES INC.?

CYPHERPUNK TECHNOLOGIES INC. trades under the ticker CYPH on NASDAQ.

Where is CYPHERPUNK TECHNOLOGIES INC. listed?

CYPHERPUNK TECHNOLOGIES INC. is listed on NASDAQ.

Which country or territory is CYPHERPUNK TECHNOLOGIES INC. listed under?

Our directory records CYPHERPUNK TECHNOLOGIES INC. under United States.

Does aibio.space cover CYPHERPUNK TECHNOLOGIES INC.?

aibio.space lists CYPHERPUNK TECHNOLOGIES INC. among 2,820 public biotech companies and publishes its news here as stories appear.

Is CYPHERPUNK TECHNOLOGIES INC. profitable?

CYPHERPUNK TECHNOLOGIES INC. reported net income of $4.8 million for the fiscal year ended Dec 31, 2025, and used $43.9 million of cash in operations, per its annual report to the SEC.

How much does CYPHERPUNK TECHNOLOGIES INC. spend on research and development?

$25.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does CYPHERPUNK TECHNOLOGIES INC. have?

$7.6 million in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: CYPHERPUNK TECHNOLOGIES INC.

Members talk about CYPHERPUNK TECHNOLOGIES INC. (CYPH). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CYPHERPUNK TECHNOLOGIES INC., newest first. Each line links the filing it comes from.

Jul 21, 2026Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
May 26, 2026Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:CYPH on TradingView.

Listing details

Company: CYPHERPUNK TECHNOLOGIES INC.
Ticker: CYPH
Listing: NASDAQ
Country or territory: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction